In Reply We agree with Dr Lloyd-Jones and colleagues that the ACC/AHA cholesterol guidelines1,2 represent progress by redirecting the focus from reducing low-density lipoprotein cholesterol levels to reducing cardiovascular risk and by promoting personalized decisions about statin use. Although the guideline literally recommends “Initiation of statin therapy for patients who are eligible for primary CVD prevention and have a predicted 10-year hard AS[atherosclerotic]CVD risk of ≥7.5%,”2(p36,Table) our Viewpoint advocated for inviting at-risk patients to engage in shared decision making about statins to reduce their risk for ASCVD.
Montori VM, Brito JP, Ting HH. Guidelines for Cardiovascular Risk Assessment and Cholesterol Treatment—Reply. JAMA. 2014;311(21):2236. doi:10.1001/jama.2014.4078